Neuraltus Pharmaceuticals Overview

  • Year Founded
  • 2004

Year Founded

  • Status
  • Out of Business

  • Employees
  • 9

Employees

  • Latest Deal Type
  • Out of Business

Neuraltus Pharmaceuticals General Information

Description

Developer of therapeutics designed to provide treatment of neurodegenerative diseases. The company's therapeutics are use to provide treatment of Lou Gehrig's disease and motor neurone disease, enabling healthcare providers to cure and understand the needs of people affected by this disease.

Contact Information

Formerly Known As
Taiji Biomedical
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 1111 Bayhill Drive
  • Suite 210
  • San Bruno, CA 94066
  • United States
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Therapeutic Devices
Vertical(s)
Corporate Office
  • 1111 Bayhill Drive
  • Suite 210
  • San Bruno, CA 94066
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Neuraltus Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Out of Business 01-Apr-2019 Completed Out of Business
8. Later Stage VC 01-Mar-2017 Completed Clinical Trials - Phase 2
7. Later Stage VC (Series A3) 24-May-2016 Completed Clinical Trials - Phase 2
6. Grant 01-Jul-2015 Completed Generating Revenue
5. Later Stage VC (Series A2) 31-May-2012 Completed Generating Revenue
4. Grant 05-Nov-2010 Completed Generating Revenue
3. Early Stage VC (Series A1) 26-Mar-2009 Completed Startup
2. Early Stage VC (Series 3) 24-Sep-2007 $624K $2.12M Completed Startup
1. Early Stage VC (Series 2) 02-Mar-2006 $1.5M $1.5M Completed Startup
To view Neuraltus Pharmaceuticals’s complete valuation and funding history, request access »

Neuraltus Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series III-1
Series II-1
Series I-1
Series A3
Series B
Series A2
Series A1
Series III
Series II 599,889 $0.001000 $0.2 $2.5 $2.5 1x $0.72 0.3%
Series I 500,000 $0.001000 $0.16 $2.01 $2.01 1x $0.72 0.2%
To view Neuraltus Pharmaceuticals’s complete cap table history, request access »

Neuraltus Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of therapeutics designed to provide treatment of neurodegenerative diseases. The company's therapeutics are us
Drug Discovery
San Bruno, CA
9 As of 2014

Blue Bell, PA
 

Palo Alto, CA
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Neuraltus Pharmaceuticals Competitors (15)

One of Neuraltus Pharmaceuticals’s 15 competitors is Mitochon Pharmaceuticals, a Venture Capital-Backed company based in Blue Bell, PA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Mitochon Pharmaceuticals Venture Capital-Backed Blue Bell, PA
Semnur Pharmaceuticals Formerly VC-backed Palo Alto, CA
NeuroNascent Venture Capital-Backed Clarksville, MD
Genentech Formerly VC-backed South San Francisco, CA
Neurona Therapeutics Formerly VC-backed South San Francisco, CA
You’re viewing 5 of 15 competitors. Get the full list »

Neuraltus Pharmaceuticals Patents

Neuraltus Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3370738-A2 Treatment of neurodegenerative disease with sodium chlorite Inactive 02-Nov-2015
US-20190060359-A1 Treatment of neurodegenerative disease with sodium chlorite Inactive 02-Nov-2015
WO-2017079161-A2 Treatment of neurodegenerative disease with sodium chlorite Inactive 02-Nov-2015
WO-2017079161-A3 Treatment of neurodegenerative disease with sodium chlorite Inactive 02-Nov-2015
AU-2015258892-A1 Methods and compositions for treatment of macrophage-related disorders Inactive 16-May-2014 A61K33/20
To view Neuraltus Pharmaceuticals’s complete patent history, request access »

Neuraltus Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Neuraltus Pharmaceuticals FAQs

  • When was Neuraltus Pharmaceuticals founded?

    Neuraltus Pharmaceuticals was founded in 2004.

  • Where is Neuraltus Pharmaceuticals headquartered?

    Neuraltus Pharmaceuticals is headquartered in San Bruno, CA.

  • What is the size of Neuraltus Pharmaceuticals?

    Neuraltus Pharmaceuticals has 9 total employees.

  • What industry is Neuraltus Pharmaceuticals in?

    Neuraltus Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Neuraltus Pharmaceuticals a private or public company?

    Neuraltus Pharmaceuticals is a Private company.

  • What is Neuraltus Pharmaceuticals’s current revenue?

    The current revenue for Neuraltus Pharmaceuticals is .

  • How much funding has Neuraltus Pharmaceuticals raised over time?

    Neuraltus Pharmaceuticals has raised $47.8M.

  • Who are Neuraltus Pharmaceuticals’s competitors?

    Mitochon Pharmaceuticals, Semnur Pharmaceuticals, NeuroNascent, Genentech, and Neurona Therapeutics are some of the 15 competitors of Neuraltus Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process